Clinical Trial

Effect of Theravex Tissue Care on Implant Stability

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this randomized clinical trial is to evaluate the clinical and radiographic outcomes of using Bone Bioactive Liquid (Theravex) compared to Xenograft and a combination therapy (Theravex + Xenograft) during immediate implant placement in the esthetic zone. When a tooth is extracted and replaced immediately with a dental implant, bone grafting is often necessary to fill the gap (jumping distance) between the implant and the surrounding bone socket to support tissue healing and maintain facial contour. Participants requiring immediate implant placement will be randomly assigned into three groups: Group 1: Immediate implant placement using Bone Bioactive Liquid (Theravex). Group 2: Immediate implant placement using Xenograft alone. Group 3: Immediate implant placement using Combination Therapy (Theravex + Xenograft). The primary outcomes will evaluate implant stability, bone dimensional changes, and soft tissue response around the implants over the follow-up period.
Trial Details
NCT Number NCT07707388
Lead Sponsor Ain Shams University
Conditions Immediate Dental Implant Placement
Enrollment 30 participants
Start Date 2026-11-12
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-09-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-16